sermorelin and Pheochromocytoma

Pheochromocytoma is a rare but potentially lethal chromaffin cell tumor with currently no effective treatment. Peptide hormone receptors are frequently overexpressed on endocrine tumor cells and can be specifically targeted by various anti-tumor peptide analogs. The present study carried out on mouse pheochromocytoma cells (MPCs) and a more aggressive mouse tumor tissue-derived (MTT) cell line revealed that these cells are characterized by pronounced expression of the somatostatin receptor 2 (sst2), growth hormone-releasing hormone (GHRH) receptor and the luteinizing hormone-releasing hormone (LHRH) receptor. We further demonstrated significant anti-tumor effects mediated by cytotoxic somatostatin analogs, AN-162 and AN-238, by LHRH antagonist, Cetrorelix, by the cytotoxic LHRH analog, AN-152, and by recently developed GHRH antagonist, MIA-602, on MPC and for AN-152 and MIA-602 on MTT cells. Studies of novel anti-tumor compounds on these mouse cell lines serve as an important basis for mouse models of metastatic pheochromocytoma, which we are currently establishing.

Topics: 2-Hydroxyphenethylamine; Adrenal Gland Neoplasms; Aniline Compounds; Animals; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cell Survival; Doxorubicin; Gonadotropin-Releasing Hormone; Growth Hormone-Releasing Hormone; Mice; Pheochromocytoma; Pyrroles; Receptors, LHRH; Receptors, Neuropeptide; Receptors, Pituitary Hormone-Regulating Hormone; Receptors, Somatostatin; Sermorelin; Somatostatin